Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial

International Clinical Psychopharmacology

Volumn 29, Issue 6, 2014, Pages 332-338

  Jeon, Hong Jin ^a,b,c   Fava, Maurizio ^c   Mischoulon, David ^c   Baer, Lee ^c   Clain, Alisabet ^c   Doorley, James ^c   DiPierro, Moneika ^c   Cardoos, Amber ^c   Papakostas, George I ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Major depressive disorder; Psychomotor symptoms; Ziprasidone

Indexed keywords

PLACEBO; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION ASSESSMENT; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SCALE SELF RATED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; COMPARATIVE STUDY; COMPLICATION; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; PSYCHOMOTOR AGITATION;

ADULT; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOMOTOR AGITATION; THIAZOLES; TREATMENT OUTCOME;

EID: 84927695623     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000039     Document Type: Article

References (34)

1. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th ed. Washington, DC: American Psychiatric Press.
2. Amsterdam JD (1998). Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 12:S99-S111.
3. Angst J, Gamma A, Benazzi F, Ajdacic V, Rossler W (2009). Does psychomotor agitation in major depressive episodes indicate bipolarity? Evidence from the Zurich study. Eur Arch Psychiatry Clin Neurosci 259:55-63.
4. Aronne LJ, Segal KR (2003). Weight gain in the treatment of mood disorders. J Clin Psychiatry 64 (Suppl 8):22-29.
5. Burns RA, Lock T, Edwards DR, Katona CL, Harrison DA, Robertson MM, et al. (1995). Predictors of response to amine-specific antidepressants. J Affect Disord 35:97-106.
6. Buyukdura JS, McClintock SM, Croarkin PE (2011). Psychomotor retardation in depression: biological underpinnings, measurement, and treatment. Prog Neuropsychopharmacol Biol Psychiatry 35:395-409.
7. Caligiuri MP, Gentili V, Eberson S, Kelsoe J, Rapaport M, Gillin JC (2003). A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. J Affect Disord 77:135-141.
8. Citrome L (2007). Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 68:1876-1885.
9. Debattista C, Solomon A, Arnow B, Kendrick E, Tilston J, Schatzberg AF (2005). The efficacy of divalproex sodium in the treatment of agitation associated with major depression. J Clin Psychopharmacol 25:476-479.
10. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S (2000). Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 60:13-23.
11. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ (2007). Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 68:1071-1077.
12. Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003). The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72:115-127.
13. Flament MF, Lane RM, Zhu R, Ying Z (1999). Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 14:259-275.
14. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
15. Han C,Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, et al. (2013). Secondgeneration antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 13:851-870.
16. Harvey PD, Siu CO, Romano S (2004). Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 172:324-332.
17. Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG (2003). Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol Bull 37:67-78.
18. Martinot M, Bragulat V, Artiges E, Dolle F, Hinnen F, Jouvent R, et al. (2001). Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 158:314-316.
19. Nemeroff CB, Lieberman JA,Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, et al. (2005). From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 10:1-20.
20. Pae CU, Patkar AA (2013). Clinical issues in use of atypical antipsychotics for depressed patients. CNS Drugs 27 (Suppl 1):S39-S45.
21. Pae CU, Jeon HJ, Lee BC, Seo HJ, Kim SG, Park EJ, et al. (2013). Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. Int Clin Psychopharmacol 28:322-329.
22. Pae CU,Wang SM, Han C, Lee SJ, Patkar AA, Masand PS (2014). Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting. Int Clin Psychopharmacol 29:116-119.
23. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, et al. (2004). Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 65:217-221.
24. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, et al. (2012). A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry 73:1541-1547.
25. Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH (2000). 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48:229-237.
26. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR∗D report. Am J Psychiatry 163:1905-1917.
27. Sechter D, Vandel P, Weiller E, Pezous N, Cabanac F, Tournoux A (2004). A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord 83:233-236.
28. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSMIV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33, Quiz 34-57.
29. Singh AB, Bousman CA, Ng CH, Byron K, Berk M (2013). Psychomotor depressive symptoms may differentially respond to venlafaxine. Int Clin Psychopharmacol 28:121-126.
30. Sobin C, Sackeim HA (1997). Psychomotor symptoms of depression. Am J Psychiatry 154:4-17.
31. Tamura RN, Huang X (2007). An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials 4:309-317.
32. Tatsumi M, Jansen K, Blakely RD, Richelson E (1999). Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 368:277-283.
33. Taylor BP, Bruder GE, Stewart JW, McGrath PJ, Halperin J, Ehrlichman H, et al. (2006). Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 163:73-78.
34. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. (2004). The Inventory of Depressive Symptomatology, Clinician Rating (IDSC) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34:73-82.